Unraveling the Frontiers of Nanomedicine: Exploring Advancements and Envisioning the Future
DOI:
https://doi.org/10.22270/ajprd.v12i4.1452Abstract
Nanomedicine is an emerging field at the junction of nanotechnology and medicine that provides high-order therapeutic solutions for different diseases. This review discusses the latest developments and future directions in nanomedicine applications in diverse areas of drug delivery, diagnostics, and tissue regeneration.Nanoparticles are engineered at the nanoscale level and, hence, play a very significant role in targeted drug delivery, improving the efficacy of drugs with reduced side effects. This has resulted in recent developments that include the functionalization of nanoparticles that can attach precisely to specific cells or tissues and stimuli-responsive nanoparticles for the controlled release of drugs depending upon environmental triggers.Nanoparticles also revolutionize medical imaging and diagnostics by acting as contrast reagents and sensitive and accurate imaging methods. In this context, SPIONs enhance magnetic resonance imaging, while gold nanoparticles improve optical imaging modalities due to their unique properties.NPs have been proven to be very useful for therapeutic applications, including cancer therapy, gene therapy, and regenerative medicine. Moreover, liposomes and polymer-based nanoparticles can deliver target drugs, lowering systemic toxicity at the tumor site. MSNPs ferry growth factors for tissue repair or act as scaffolds for cell transplantation.Compared to all of the possible benefits of nanomedicine, ensuring the safety and nontoxicity of nanoparticles overwhelmingly comes first. Researchers are working on analyses of the long-term interactions between nanoparticles and biological systems and developing appropriate regulatory frameworks that will enable the safe and responsible use of these materials.The potential for nanomedicine to create opportunities in personalized medicine, combined therapies, and "smart" treatments is considerable. However, to come up with that kind of future vision, enormous challenges lie in the pathway forward—which especially includes regulatory approval and the creation of scalable pathways for manufacturing.
Downloads
References
National Cancer Institute. Current Treatments [Internet]. Bethesda: National Cancer Institute; [cited 2024 Jul 10]. Available from: https://www.cancer.gov/nano/cancer-nanotechnology/current-treatments
European Technology Platform on Nanomedicine. What Is Nanomedicine? [Internet]. European Technology Platform on Nanomedicine; [cited 2024 Jul 10]. Available from: https://etp-nanomedicine.eu/about-nanomedicine/what-is-nanomedicine/
Pilli GD, Elumalai K, Muthukumar VA, Sundaram PS. A revised analysis of current and emerging Nano suspension technological approaches for cardiovascular medicine. Beni-Suef University Journal of Basic and Applied Sciences. 2022 Jan 15;11(1):10.
Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, Okoroafor CC, Eze SC, Kalu OL, Odoh EC, Nwadike UG. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023 Jun 1;9(6).
Choi YH, Han HK. Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. Journal of pharmaceutical investigation. 2018 Jan;48(1):43-60.
Feynman R. There’s plenty of room at the bottom. Eng Sci. 1960;23:22-36.
Barenholz YC. Doxil®—The first FDA-approved nano-drug: Lessons learned. Journal of controlled release. 2012 Jun 10;160(2):117-34.
Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Frontiers in molecular biosciences. 2020 Aug 20;7:193.
Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Advanced drug delivery reviews. 2006 Dec 1;58(14):1456-9.
Jain KK. Advances in the field of nanomedicine. Drug Discov Today. 2015;20(2):145-52.
D’Costa G, Pisal DS, Rane AV. Report on Synthesis of nanoparticles and functionalization: Co precipitation method.
Cheng X, Xie Q, Sun Y. Advances in nanomaterial-based targeted drug delivery systems. Frontiers in bioengineering and biotechnology. 2023 Apr 13;11:1177151.
Pantidos N, Horsfall LE. Biological synthesis of metallic nanoparticles by bacteria, fungi and plants. Journal of Nanomedicine & Nanotechnology. 2014 Sep 1;5(5):1.
Singh R, Lillard Jr JW. Nanoparticle-based targeted drug delivery. Experimental and molecular pathology. 2009 Jun 1;86(3):215-23.
Bahrami B, Hojjat-Farsangi M, Mohammadi H, Anvari E, Ghalamfarsa G, Yousefi M, Jadidi-Niaragh F. Nanoparticles and targeted drug delivery in cancer therapy. Immunology letters. 2017 Oct 1;190:64-83.
Desai N. Nab-paclitaxel formulation: Abraxane®. The Oncologist. 2006;12(7):902-12.
Zhao M, Lei C, Yang Y, Bu X, Ma H, Gong H, Liu J, Fang X, Hu Z, Fang Q. Abraxane, the nanoparticle formulation of paclitaxel can induce drug resistance by up-regulation of P-gp. PloS one. 2015 Jul 16;10(7):e0131429.
Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology. 1990 May;175(2):494-8.
Chen Y, Yang J, Fu S, Wu J. Gold nanoparticles as radiosensitizers in cancer radiotherapy. International Journal of nanomedicine. 2020 Nov 24:9407-30.
Chen F, Ehlerding EB, Cai W. Theranostic nanoparticles. Journal of nuclear medicine. 2014 Dec 1;55(12):1919-22.
Chaudhury K, Kumar V, Kandasamy J, RoyChoudhury S. Regenerative nanomedicine: current perspectives and future directions. International journal of nanomedicine. 2014 Sep 1:4153-67.
Patel P, Shah J. Safety and toxicological considerations of nanomedicines: the future directions. Current Clinical Pharmacology. 2017 May 1;12(2):73-82.
Wolfram J, Zhu M, Yang Y, Shen J, Gentile E, Paolino D, Fresta M, Nie G, Chen C, Shen H, Ferrari M. Safety of nanoparticles in medicine. Current drug targets. 2015 Dec 1;16(14):1671-81.
Lombardo D, Kiselev MA, Caccamo MT. Smart nanoparticles for drug delivery application: development of versatile nanocarrier platforms in biotechnology and nanomedicine. Journal of nanomaterials. 2019;2019(1):3702518.
Zhang RX, Wong HL, Xue HY, Eoh JY, Wu XY. Nanomedicine of synergistic drug combinations for cancer therapy–Strategies and perspectives. Journal of Controlled Release. 2016 Oct 28;240:489-503.
Nune SK, Gunda P, Thallapally PK, Lin YY, Laird Forrest M, Berkland CJ. Nanoparticles for biomedical imaging. Expert opinion on drug delivery. 2009 Nov 1;6(11):1175-94.
Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: Structure, composition, types, and clinical applications. Heliyon. 2022 May 1;8(5).
28.Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Frontiers in molecular biosciences. 2020 Aug 20;7:193.
U.S. Food and Drug Administration. (n.d.). Guidance for Industry: Safety of Nanomaterials in Cosmetic Products. Retrieved from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-safety-nanomaterials-cosmetic-products.
Hasan A, Morshed M, Memic A, Hassan S, Webster TJ, Marei HE. Nanoparticles in tissue engineering: applications, challenges and prospects. International journal of nanomedicine. 2018 Sep 24:5637-55.
Hong IS. Enhancing stem cell-based therapeutic potential by combining various bioengineering technologies. Frontiers in Cell and Developmental Biology. 2022 Jul 5;10:901661.
Wolfram J, Zhu M, Yang Y, Shen J, Gentile E, Paolino D, Fresta M, Nie G, Chen C, Shen H, Ferrari M. Safety of nanoparticles in medicine. Current drug targets. 2015 Dec 1;16(14):1671-81.
Rashid MM, Forte Tavčer P, Tomšič B. Influence of titanium dioxide nanoparticles on human health and the environment. Nanomaterials. 2021 Sep 10;11(9):2354.
Xuan L, Ju Z, Skonieczna M, Zhou PK, Huang R. Nanoparticles‐induced potential toxicity on human health: applications, toxicity mechanisms, and evaluation models. MedComm. 2023 Aug;4(4):e327.
Published
Versions
- 2024-08-15 (2)
- 2024-08-15 (1)
How to Cite
Issue
Section
Copyright (c) 2024 Shivam Rongpi, Injamul Islam, Ananta Choudhury, Dr. Rajesh Kumar Sharma, Charlisar Teron
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.